A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
A study for patients with Acute Myeloid Leukemia (AML) using study drug ASP2215
Sponsor: Astellas
Enrolling: Male and Female Patients
IRB Number: AAAQ5660
U.S. Govt. ID: NCT02421939
Contact: Joseph Jurcic: 646-317-5077 / jgj2110@cumc.columbia.edu
Additional Study Information: The purpose of the study is to see if a medicine called ASP2215 is both effective and safe as atreatment for AML patients with mutations in FLT3 gene identified by an investigational FLT3Mutation Assay companion diagnostic (a specific way to test your blood or bone marrow, which is used to see if you have a mutation of the FLT3 gene), compared to salvage chemotherapy.
This study is closed
Investigator
Joseph Jurcic, MD
Do You Qualify?
Have you been diagnosed with primary acute myeloid leukemia (AML) or AML secondary to myelodysplastic syndrome (MDS)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Joseph Jurcic
jgj2110@cumc.columbia.edu
646-317-5077
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE